Shorter hormone therapy as effective as longer course for prostate cancer

09/25/2013 | U.S. News & World Report

Short-term hormone therapy after radiation treatment had a comparable effect on overall survival and disease-specific survival as longer-course therapy in men with intermediate-risk prostate cancer, according to a study presented at a meeting of the American Society for Radiation Oncology. In the study of 133 patients, disease-specific survival was 96% for both short- and long-term hormone therapy groups while 10-year overall survival was 61% in the shorter-course group and 65% in the long-term group.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI